The Top 5 Biosimilars Articles for the Week of October 7
The Center for Biosimilars® recaps the top stories for the week of October 7, 2019.
Transcript
Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of October 7, 2019.
Number 5: A new study reports that, for children who switch to biosimilars, factors like device type, citrates, and even color can be primary concerns.
Number 4: The Institute for Clinical and Economic Review says that brand-name adalimumab, rituximab, and pegfilgrastim, all of which have approved biosimilars, have seen substantial increases to price that have not been supported by new clinical data.
Number 3: Nevada’s Department of Health and Human Services sent letters to drug firms that did not provide required information about their costs, and it issued $17.4 million in penalties for noncompliance.
Number 2: The FDA has approved Pfenex’s follow-on teriparatide, referencing Forteo, for the treatment of osteoporosis.
Number 1: The FDA has issued a complete response letter for Tanvex’s proposed filgrastim biosimilar.
Finally, last week, our e-newsletter asked whether you think that the United States should allow external reference pricing to help reduce drug costs.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.
